Dhruv Khullar is a contributing writer at The New Yorker. He focuses on medicine, health care, and politics, with a particular interest in value-based care, health disparities, and medical innovation, along with topics such as diet and nutrition and wellness programs. Khullar's work has been featured in outlets including JAMA, Environmental Health News, and TED Conferences.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
This information evolves through artificial intelligence and human feedback. Improve this profile .
Large language models are transforming medicine—but the technology comes with side effects.
As confidence in the C.D.C. wanes, states are asserting more control over their vaccine policies, creating a fragmented public-health system.
The Department of Health and Human Services maintains that it is hewing to “gold standard, evidence-based science”—doublespeak that might unsettle Orwell.
Some patients don’t trust us. Others say they don’t need us. It’s time for us to think of ourselves not as the high priests of health care but as what we have always been: healers.
. “The Pitt” handles each of these themes, and many more, with nuance and grace. It's as if the show's creators absorbed every important conversation in health care today—and somehow transfigured it into good television.
Health and wellness influencers are hawking unapproved treatments on the gray market. The future of the F.D.A.—and the health of consumers—is at stake.
The outbreaks of hantavirus and Ebola expose the shortsightedness of America's retreat, under the Trump Administration, from its role as a global-health leader.
What if GLP-1s like Ozempic could do more than just tip the scales? Physician Dhruv Khullar traces the winding path of the "moderation molecule" — from a discovery in Gila monster saliva to a potential diabetes medication and addiction treatment — and how they could quiet the relentless noise of craving. The most surprising effects of GLP-1s may not be in the gut, but in the brain.
Jiroemon Kimura, who is on record as the world's oldest man, died at the reported age of a hundred and sixteen, in 2013.
From the daily newsletter: maybe the goal should be to live meaningfully, instead of just longer.
